23:33 , Jun 17, 2019 |  BC Extra  |  Company News

Sanofi shies away from neuro gene therapy programs

Changes to two partnerships this year suggest Sanofi is paring down the disease areas in which it wants to deploy gene therapy. The latest came on Monday, when Voyager Therapeutics Inc. (NASDAQ:VYGR) said it and...
22:27 , Jun 14, 2019 |  BC Extra  |  Company News

Management tracks: Flatiron picks Unum’s Vasconcelles to succeed Abernethy; plus Quell, Lytix and more

Flatiron Health Inc. hired Michael Vasconcelles as CMO. Vasconcelles, who was CMO of Unum Therapeutics Inc. (NASDAQ:UMRX), succeeds Amy Abernethy, who left to join FDA as principal deputy commissioner early this year. The Roche (SIX:ROG;...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
23:55 , Jun 12, 2019 |  BioCentury  |  Finance

How Bain plans to deploy $1B new fund

Bain Capital Life Sciences’ larger second fund could see the firm increasing its emphasis on investing in big biopharma spinouts after its debut fund featured investments in a pair of megarounds by Pfizer spin-offs. Bain...
23:49 , Jun 7, 2019 |  BioCentury  |  Politics, Policy & Law

Levitating Levin: new chair’s ambitious plans to elevate BIO

Jeremy Levin has been talking for years about ways to elevate biopharma business practices and public policy to bypass obstacles that hold back biomedical innovation. As BIO’s new chair, he has a chance to try...
00:28 , Jun 7, 2019 |  BioCentury  |  Product Development

How early biomarkers and constant iteration fuel Vertex's R&D efficiency

As Vertex prepares its fourth NDA for a cystic fibrosis drug in six years, EVP of Global Research and CSO David Altshuler credits the biotech’s R&D efficiency to a focus on agents that show more...
00:21 , Jun 1, 2019 |  BioCentury  |  Product Development

SMA drug Zolgensma’s label more surprising than its price

FDA surprised Novartis, patient advocates and physicians by approving a label for the pharma’s gene therapy that creates hope that newborns diagnosed with spinal muscular atrophy can be treated before symptoms appear -- in time...
21:09 , May 24, 2019 |  BC Extra  |  Company News

AveXis says label makes Zolgensma gene therapy ‘treatment of choice’ for newly diagnosed SMA

Gene therapy Zolgensma from Novartis’ AveXis unit received a label from FDA that will allow it to become the “treatment of choice” for newly diagnosed spinal muscular atrophy patients, according to the company, as well...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
22:37 , May 23, 2019 |  BC Extra  |  Company News

Impasse over Vertex CF drugs likely to continue despite NHS’s managed access offer

Despite including a key request from CF patient advocacy groups' wish list, a fresh proposal from NHS England is unlikely to break the three-year-long stalemate over access to Vertex's cystic fibrosis drugs. NHS England's new...